Skip to main content
. 2020 Feb 27;5(4):e133977. doi: 10.1172/jci.insight.133977

Figure 9. TGFBR2-KO CAR T cells have potent and persistent tumor elimination efficacy in PDX tumor 2 model.

Figure 9

(A) Expression of mesothelin and TGF-β1 on PDX tumor 2. Scale bar: 200 μm. (B) Fold change of tumor volume after i.t. CAR T cell administration in PDX model 2. (C) Fold change of tumor volume after PDX tumor 2 reinoculation. (D) Tumor sizes and weights were detected at the end of the PDX tumor 2 reinoculation experiment. M28z-TKO, TGFBR2-KO M28z; i.t., intratumor; PB, peripheral blood; un, undetectable. Mean ± SD, n = 5, except in D. Two-way ANOVA and Tukey’s multiple comparisons test were used in B and C. Unpaired t test was used in D.